ADAM17 and ovarian carcinoma: Very recently, Sun et al. demonstrated that the treatment of cisplatin resistant ovarian cancer cells with the anti-PD-1 antibody Nivolumab led to downregulation of ADAM17 expression and increased apoptosis in these cell lines (Skov-3 and cisplatin resistant A2780 cells (A2780-DDP)) [51].